The Environmental Cost Of Production: Will Big Pharma Be On The Hook For API Hazards?
This article was originally published in PharmAsia News
Executive Summary
Many companies source their active pharmaceutical ingredients from India and China to cut costs, but well-publicized reports of environmental hazards around these API facilities are adding additional costs and raising ethical and safety concerns, and regulators are weighing options to control the environmental impact of drug production
You may also be interested in...
India Plans Taskforce To Deal With Pharmaceutical Environmental Issues
NEW DELHI - The Indian government will soon constitute a taskforce to assess the impact of drug manufacturing on the environment and find amicable solutions, Department of Pharmaceuticals Secretary Ashok Kumar announced Feb. 12 at an industry seminar in New Delhi
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).